Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
83% Article relates to my practice (5/6)
16% Article does not relate to my practice (1/6)
0% Undecided (0/6)
2

Will this article lead to more cost-effective healthcare?

66% Yes (4/6)
16% No (1/6)
16% Undecided (1/6)
3

Was this article biased? (commercial or personal)

0% Yes (0/6)
100% No (6/6)
0% Undecided (0/6)
4

What level of evidence do you think this article is?

0% Level 1 (0/6)
0% Level 2 (0/6)
66% Level 3 (4/6)
16% Level 4 (1/6)
16% Level 5 (1/6)